1) Formulation and optimization of a palatable, high-bioavailability polymeric nanoparticle drug delivery system for poorly water-soluble anticancer agents.

Project Abstract

Formulation and optimization of a palatable, high-bioavailability polymeric nanoparticle drug delivery system for poorly water-soluble anticancer agents presents a strategic approach to overcoming the limitations of conventional chemotherapy, including poor aqueous solubility, limited oral bioavailability, systemic toxicity, and non-specific distribution. This study aims to design a robust, patient-friendly nanoparticulate platform that enhances solubility, protects the active pharmaceutical ingredient from degradation, and achieves targeted tumor accumulation with reduced off-target effects. A multidisciplinary methodology was employed, integrating polymer science, pharmaceutical formulation, in vitro and in vivo evaluations, and computational modeling to identify optimal physicochemical characteristics that govern solubility enhancement, stability, and release kinetics. Initially, a library of biocompatible polymers and amphiphilic block copolymers was screened to formulate nanoparticles encapsulating poorly soluble anticancer agents such as paclitaxel, camptothecin derivatives, and daunorubicin. The optimization employed a quality-by-design (QbD) framework, focusing on critical quality attributes including particle size (target 50–150 nm), zeta potential (±20–30 mV for stability), drug loading efficiency, encapsulation efficiency, and controlled release profiles under physiological conditions. Surface modification with hydrophilic polymers (e.g., PEG) and targeting ligands (e.g., folate or transferrin) was explored to enhance circulation time and tumor specificity. Palatability was addressed by incorporating taste-masking excipients and oral disintegration properties without compromising nanoparticle integrity or release dynamics. Characterization techniques encompassed dynamic light scattering, transmission electron microscopy, differential scanning calorimetry, Fourier-transform infrared spectroscopy, and X-ray diffraction to confirm amorphous dispersion and polymer-drug interactions. In vitro release studies were conducted in simulated gastric and intestinal fluids to assess sensory-friendly administration and to model sequential release behavior. Biocompatibility and cytotoxicity were evaluated against a panel of cancer cell lines and healthy cell controls to determine therapeutic selectivity. Cellular uptake and intracellular trafficking were investigated using confocal microscopy and flow cytometry, elucidating endocytic pathways and endosomal escape mechanisms relevant to enhanced intracellular drug delivery. In vivo pharmacokinetic and biodistribution studies in rodent models evaluated oral bioavailability, plasma concentration-time profiles, tissue accumulation, and clearance, with a comparative assessment against conventional formulations. Efficacy studies examined tumor growth inhibition, survival benefits, and histopathological analyses to assess potential reductions in systemic toxicity. Stability assessments under accelerated and real-time conditions informed shelf-life projection. A translational framework was developed to demonstrate scalability, reproducibility, and regulatory readiness, including GMP-compatible manufacturing considerations and quality control strategies. Preliminary findings indicate that the optimized polymeric nanoparticles substantially improve solubility and oral bioavailability of poorly soluble anticancer agents, while maintaining desirable release kinetics and enhanced tumor targeting. Taste-masking strategies did not adversely affect bioavailability, and in vivo results suggested improved therapeutic index with reduced off-target organ exposure. The study advances a versatile platform capable of adapting to a range of hydrophobic anticancer drugs, offering a promising pathway toward more effective, patient-friendly chemotherapy regimens with minimized systemic toxicity.

Project Overview

What This Project Is About

---

The project looks at making tiny drug carriers called polymeric nanoparticles that can carry anticancer drugs which don’t dissolve well in water. The goal is to make these carriers easy to swallow (palatable), safe, and able to release the drug effectively in the body so it can fight cancer more efficiently.

---

---

The Problem It Addresses

---

Chemical anticancer drugs often don’t dissolve well in water, which can limit how much of the drug reaches the tumor. Traditional formulations can cause side effects and poor patient experience. This project aims to improve solubility, targeting, and taste, reducing dosing issues and enhancing therapy.

---

---

Objectives of the Project

---

1. Design a polymer-based nanoparticle that carries poorly soluble anticancer drugs.
2. Improve the drug’s solubility and stability in biological fluids.
3. Enhance oral palatability without compromising efficacy.
4. Optimize how the drug is released over time to maximize effect.
5. Evaluate safety and basic biocompatibility in simple tests.

---

---

What You Will Do Step by Step

---

1. Review existing literature on polymeric nanoparticles and poorly soluble drugs.
2. Select suitable polymers and formulation methods to create nanoparticles.
3. Prepare and characterize nanoparticles (size, uniformity, stability).
4. Test solubility improvements and in vitro release profiles.
5. Assess palatability through simple taste/texture evaluations.
6. Study preliminary safety through basic biocompatibility tests.
7. Analyze data to identify the best formulation and prepare a report.

---

---

Expected Outcome

A validated nanoparticle formulation that improves solubility and provides palatable, controlled release of an anticancer drug, with evidence of safety and potential for further development.